论文部分内容阅读
对１０例肾移植患者应用与未用更昔洛韦后环孢菌素Ａ的药动学参数及临床生化指标进行研究。采用荧光偏振免疫法测定血药浓度，３Ｐ８７程序拟合药动学参数。结果显示：应用更昔洛韦后，环孢菌素Ａ药动学参数Ｋｅ、ｔ１／２（Ｋａ）分别由未用组的（０．１６±０．０４）ｈ－１和（１．３９±０．７６）ｈ降至（０．０９±０．０５）ｈ－１和（０．５０±０．３２）ｈ（Ｐ＜０．０５），Ｔｍａｘ由（３．６７±０．７７）ｈ减至（２．００±０．７８）ｈ（Ｐ＜０．０１），ｔ１／２（Ｋｅ）由（４．０８±１．８５）ｈ增至（１０．５１±６．４２）ｈ（Ｐ＜０．０５），峰浓度Ｃｍａｘ平均升高２７％。肾移植后应用更昔洛韦组肾功指标下降，肝功指标上升，其中血清肌酐、总胆红质与未用组相比有统计学意义。表明更昔洛韦使肾移植患者环孢菌素Ａ的药动学参数及临床生化指标发生改变，提示临床调整用药方案。
Pharmacokinetic parameters and clinical biochemical parameters of cyclosporin A in 10 renal transplant recipients with and without ganciclovir were studied. Fluorescence polarization immunoassay was used to determine plasma concentration, and the 3P87 program fitted pharmacokinetic parameters. The results showed that the pharmacokinetic parameters Ke, t1 / 2 (Ka) of cyclosporine A were changed from those of the untreated group to (0.16 ± 0.04) h-1 and (1.39 ± 0.76) h to (0.09 ± 0.05) h-1 and (0.50 ± 0.32) h respectively (P <0.05) h decreased from (4.08 ± 1.85) h to (10.51 ± 6.42) h (2.00 ± 0.78) h (P <0.01) (P <0.05), and the peak concentration Cmax increased by 27% on average. Renal function decreased after ganciclovir administration and liver function index increased after renal transplantation. Serum creatinine and total bilirubin were statistically significant compared with unused group. That ganciclovir renal transplant patients cyclosporin A pharmacokinetic parameters and clinical biochemical changes, suggesting that the clinical adjustment of drug regimens.